Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

94 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Corrigendum to 'Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein' [Pharmacol. Res. 175 (2022) 105975].
Abd-Ellatef GEF, Gazzano E, El-Desoky AH, Hamed AR, Kopecka J, Belisario DC, Costamagna C, Marie MAS, Fahmy SR, Abdel-Hamid AZ, Riganti C. Abd-Ellatef GEF, et al. Among authors: gazzano e. Pharmacol Res. 2023 Mar;189:106708. doi: 10.1016/j.phrs.2023.106708. Epub 2023 Mar 2. Pharmacol Res. 2023. PMID: 36868967 Free article. No abstract available.
Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells.
Fathy Abd-Ellatef GE, Gazzano E, Chirio D, Hamed AR, Belisario DC, Zuddas C, Peira E, Rolando B, Kopecka J, Assem Said Marie M, Sapino S, Ramadan Fahmy S, Gallarate M, Abdel-Hamid AZ, Riganti C. Fathy Abd-Ellatef GE, et al. Among authors: gazzano e. Pharmaceutics. 2020 Jan 24;12(2):96. doi: 10.3390/pharmaceutics12020096. Pharmaceutics. 2020. PMID: 31991669 Free PMC article.
Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer.
Salaroglio IC, Gazzano E, Abdullrahman A, Mungo E, Castella B, Abd-Elrahman GEFA, Massaia M, Donadelli M, Rubinstein M, Riganti C, Kopecka J. Salaroglio IC, et al. Among authors: gazzano e. J Exp Clin Cancer Res. 2018 Nov 27;37(1):286. doi: 10.1186/s13046-018-0967-0. J Exp Clin Cancer Res. 2018. PMID: 30482226 Free PMC article.
ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.
Salaroglio IC, Mungo E, Gazzano E, Kopecka J, Riganti C. Salaroglio IC, et al. Among authors: gazzano e. Int J Mol Sci. 2019 May 21;20(10):2505. doi: 10.3390/ijms20102505. Int J Mol Sci. 2019. PMID: 31117237 Free PMC article. Review.
Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I, Gazzano E, Jean SR, Audrito V, Kopecka J, Fanelli M, Salaroglio IC, Costamagna C, Roato I, Mungo E, Hattinger CM, Deaglio S, Kelley SO, Serra M, Riganti C. Buondonno I, et al. Among authors: gazzano e. Mol Cancer Ther. 2016 Nov;15(11):2640-2652. doi: 10.1158/1535-7163.MCT-16-0048. Epub 2016 Jul 27. Mol Cancer Ther. 2016. PMID: 27466354
94 results